MeritValue

U S PHYSICAL THERAPY INC /NV

USPHdata completeness 100%17 fiscal years on file
The thesis, from the filings

U S PHYSICAL THERAPY INC /NV earns about 10% on invested capital, barely covering its ~9% cost of capital, but has diluted owners by 18% over 5 years — worth asking whether the growth reaches owners. The estimate methods put fair value between $21.19 and $50.49 a share. Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$495M1$553.1M2$604.8M3$671.3M3$781M3
Net income$40.8M4$32.2M5$28.2M6$31.4M6$39.6M6
Operating cash flow$76.4M7$58.5M8$82M9$74.9M9$75.1M9
Capital expenditure$8.2M10$8.25M11$9.29M12$9.19M12$14.1M12
Free cash flow (derived)$68.2M7,10$50.3M8,11$72.7M9,12$65.8M9,12$61M9,12
Total debt$118.4M13$183.7M14,15$146.7M16,17$153.5M18,19$162.5M18,19
Cash & equivalents$28.6M20$31.6M21$152.8M22$41.4M23$35.6M23
Diluted shares12.9M13.0M14.2M15.1M15.2M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$313.96
your share of equity
Profit it earned you last year
$26.08
Free cash flow it threw off
$40.19
Debt you’d be carrying
$107.06

10 shares is a claim on $313.96 of net worth that earned you $26.08 and generated $40.19 of cash last year, against $107.06 of debt.

iii. Is this a good business?
Moat signal · return on invested capital
10% avg · 5y
FY21 15%FY22 9%FY23 8%FY24 8%FY25 10%

It earned about 10% on invested capital against a ~9% cost of capital — roughly what it costs to fund the business, so the numbers show no clear edge.

seeing a moat in the numbers →
Management signal · capital allocation
+18% shares · 5y

Share count is up 18% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 37% over the same window.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.6.0

The 3 estimate methods that apply put fair value between $21.19 and $50.49 a share. They rest on different assumptions, so where they diverge is the story; the Graham Number is a conservative ceiling on what a defensive investor should pay, not a target.

DCF · Growth Exit 10Y
$46.15
assumptions (10)
  • Risk-free rate (10Y Treasury)5.00%
  • Equity risk premium5.00%
  • Beta (β)1.00
  • Equity share of capital85.0%
  • Debt spread over risk-free1.50%
  • Tax rate21.0%
  • Terminal growth2.50%
  • Projection period10 years
  • FCF growth0.0%
  • Starting free cash flow$65.8M
DCF · Growth Exit 5Y
$50.49
assumptions (10)
  • Risk-free rate (10Y Treasury)5.00%
  • Equity risk premium5.00%
  • Beta (β)1.00
  • Equity share of capital85.0%
  • Debt spread over risk-free1.50%
  • Tax rate21.0%
  • Terminal growth2.50%
  • Projection period5 years
  • FCF growth0.0%
  • Starting free cash flow$65.8M
Earnings Power Value
$21.19
assumptions (8)
  • Risk-free rate (10Y Treasury)5.00%
  • Equity risk premium5.00%
  • Beta (β)1.00
  • Equity share of capital85.0%
  • Debt spread over risk-free1.50%
  • Tax rate21.0%
  • Normalized earnings$32.2M
  • Growth assumed0.0%
Graham Number
$31.67
assumptions (1)
  • Graham multiplier (P/E × P/B)22.5×

Different models answer different questions — which to trust when →

v. The price question — last, on purpose
Is today’s price fair?
See live price ↗
Type a price. The ledger answers.
Or set your own belief
FCF growth, next 5 years0.0%
Discount rate (WACC)9.27%
Terminal growth2.5%
At your growth, a share is worth $50.49
The three cases
Bear0.0%$50.49
Base0.0%$50.49
Bull5.0%$64.64

Bear/base/bull growth = 0% / filed history / history + 5pp. Type a price to see the return each case implies.

Default growth 0.0%= this company’s own filed history (median-to-median FCF CAGR, clamped 0–20%). Your adjustments are recorded anonymously. They become the “what do owners actually believe” dataset.

Beyond this page

This page is free, and so is every other company on MeritValue.

In your AI assistant

Connect the MeritValue MCP server to Claude or another MCP client, ask about U S PHYSICAL THERAPY INC /NV, and get these exact figures with their filing receipts — not an improvised DCF.

Get a free key →
Screen by model

Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.

See pricing →
On iPhone

Follow USPH and keep your own price beside the value. The same engine, with the same receipts.

MeritValue on the App Store →
Sources — the receipts
  1. 10-K filed 2024-02-29 · period ending 2021-12-31 · accession 0001140361-24-010454 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K filed 2025-03-03 · period ending 2022-12-31 · accession 0001140361-25-006750 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K filed 2026-02-27 · periods ending 2023-12-31, 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K filed 2024-02-29 · period ending 2021-12-31 · accession 0001140361-24-010454 (NetIncomeLoss)
  5. 10-K filed 2025-03-03 · period ending 2022-12-31 · accession 0001140361-25-006750 (NetIncomeLoss)
  6. 10-K filed 2026-02-27 · periods ending 2023-12-31, 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (NetIncomeLoss)
  7. 10-K filed 2024-02-29 · period ending 2021-12-31 · accession 0001140361-24-010454 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K filed 2025-03-03 · period ending 2022-12-31 · accession 0001140361-25-006750 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K filed 2026-02-27 · periods ending 2023-12-31, 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K filed 2024-02-29 · period ending 2021-12-31 · accession 0001140361-24-010454 (PaymentsToAcquireProductiveAssets)
  11. 10-K filed 2025-03-03 · period ending 2022-12-31 · accession 0001140361-25-006750 (PaymentsToAcquireProductiveAssets)
  12. 10-K filed 2026-02-27 · periods ending 2023-12-31, 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (PaymentsToAcquireProductiveAssets)
  13. 10-K filed 2022-03-01 · period ending 2021-12-31 · accession 0001140361-22-007247 (LongTermDebt)
  14. 10-K filed 2024-02-29 · period ending 2022-12-31 · accession 0001140361-24-010454 (LongTermDebtNoncurrent)
  15. 10-K filed 2024-02-29 · period ending 2022-12-31 · accession 0001140361-24-010454 (LongTermDebtCurrent)
  16. 10-K filed 2025-03-03 · period ending 2023-12-31 · accession 0001140361-25-006750 (LongTermDebtNoncurrent)
  17. 10-K filed 2025-03-03 · period ending 2023-12-31 · accession 0001140361-25-006750 (LongTermDebtCurrent)
  18. 10-K filed 2026-02-27 · periods ending 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (LongTermDebtNoncurrent)
  19. 10-K filed 2026-02-27 · periods ending 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (LongTermDebtCurrent)
  20. 10-K filed 2023-02-28 · period ending 2021-12-31 · accession 0001140361-23-009198 (CashAndCashEquivalentsAtCarryingValue)
  21. 10-K filed 2024-02-29 · period ending 2022-12-31 · accession 0001140361-24-010454 (CashAndCashEquivalentsAtCarryingValue)
  22. 10-K filed 2025-03-03 · period ending 2023-12-31 · accession 0001140361-25-006750 (CashAndCashEquivalentsAtCarryingValue)
  23. 10-K filed 2026-02-27 · periods ending 2024-12-31, 2025-12-31 · accession 0001140361-26-007170 (CashAndCashEquivalentsAtCarryingValue)